These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 31702857)

  • 1. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
    Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
    Reusch J; Andersen JT; Rant U; Schlothauer T
    MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and screening of IgG binding to the neonatal Fc receptor.
    Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
    MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
    Sun Y; Estevez A; Schlothauer T; Wecksler AT
    MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
    Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
    Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc-engineered antibodies with immune effector functions completely abolished.
    Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
    PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.